• Citer

Gadolinium-based nanoparticles and radiation therapy for multiple brain melanoma metastases: Proof of concept before phase I trial

par Kotb, Shady;Rodriguez-Lafrasse, Claire;Verry, Camille;Berbeco, Ross;Tillement, Olivier;Sancey, Lucie;Detappe, Alexandre;Lux, François;Appaix, Florence;Barbier, Emmanuel Luc;Tran, Vu Long;Plissonneau, Marie;Gehan, Hélène;Lefranc, Florence
Référence Theranostics, 6, 3, page (418-427)
Publication Publié, 2016

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Nanoparticles containing high-Z elements are known to boost the efficacy of radiation therapy. Gadolinium (Gd) is particularly attractive because this element is also a positive contrast agent for MRI, which allows for the simultaneous use of imaging to guide the irradiation and to delineate the tumor. In this study, we used the Gd-based nanoparticles, AGuIX®. After intravenous injection into animals bearing B16F10 tumors, some nanoparticles remained inside the tumor cells for more than 24 hours, indicating that a single administration of nanoparticles might be sufficient for several irradiations. Combining AGuIX® with radiation therapy increases tumor cell death, and improves the life spans of animals bearing multiple brain melanoma metastases. These results provide preclinical proof-of-concept for a phase I clinical trial.